All posts

Corus Entertainment gets price target cut at Canaccord Genuity

Expect a drop in EBITDA and lower TV ad and content revenues over the second half of 2018 from Corus Entertainment (Corus Entertainment Stock Quote, Chart, News: TSX:CJR.B), says Aravinda Galappatthige, analyst with Canaccord Genuity, who in a Thursday update to clients maintained his “Hold” rating but lowered his target price for Corus to C$7.00.

Q2/FY18 financial results are in for specialty TV and radio company Corus Entertainment, with the company reporting an EBITDA of $112.8 million, beating the consensus estimate by 15.6 per cent and Galappatthige’s estimate by 13.5 per cent. But it’s the flat revenue stream and poor visibility that are problematic to the analyst.

“While the stock unsurprisingly rebounded following the Q2 results, particularly given the steep downswing in the run up to the quarter, the outlook for TV ad trends in H2 remains difficult to call,” says the analyst.

“While no specific tracking for Q3 was provided, we certainly sensed some cautiousness around the comments. Given the relatively tough base in H2/17 (where Corus actually stabilized ad revenues), we have conservatively assumed ~5 per cent decline in TV ad revenues in H2,” he says. “Management also alluded to lower Content revenues in H2 due to timing. Finally, Q3 is likely to see higher programming costs due to some of the delayed spend (post Olympics) hitting the quarter. Factoring in the above, we have lowered our estimates and now expect a 9 per cent decline in corporate EBITDA in H2/18.”

Galappatthige says investors should expect to see a 50 to 70 per cent dividend cut along with the upcoming Q3 results or, if no dividend cut, then he sees leverage move up to 3.6x by the end of fiscal 2019.

The analyst has lowered his FY 2018 and 2019 EBITDA estimates for Corus to $547.8 million (down from $553.1 million) and $508.7 million (down from $535.4 million), respectively.

Galappatthige’s price target for Corus has been lowered from $9.00 to $7.00, representing a projected return on investment of negative 2.2 per cent.

Tagged with: cjr.b
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Verano Holdings is undervalued, Haywood says

Haywood Capital Markets analyst Neal Gilmer says Verano Holdings (Verano Holdings Stock Quote, Chart, News, Analysts, Financials NEO:VRNO) is staying… [Read More]

2 days ago

Knight Therapeutics is a buy, Stifel says

Knight Therapeutics (Knight Therapeutics Stock Quote, Chart, News, Analysts, Financials TSXV:GUD) is continuing to build momentum, according to Stifel Nicolaus… [Read More]

2 days ago

Groupon wins price target raise at Roth

Roth Capital Partners has raised its price target on Groupon (Groupon Inc Stock Quote, Chart, News, Analysts, Financials NASDAQ:GRPN) to… [Read More]

2 days ago

Trulieve Cannabis is a buy, Beacon says

Trulieve Cannabis (Trulieve Cannabis Stock Quote, Chart, News, Analysts, Financials CSE:TRUL) delivered a strong start to fiscal 2025, beating high-end… [Read More]

2 days ago

Green Thumb Industries should be a core holding for cannabis investors, analyst says

Green Thumb Industries (Green Thumb Industries Stock Quote, Chart, News, Analysts, Financials CSE:GTII) delivered a steady first quarter and remains… [Read More]

2 days ago

5N Plus just delivered an “exceptional” quarter, this analyst says

5N Plus (5N Plus Stock Quote, Chart, News, Analysts, Financials TSX:VNP) blew past expectations in the first quarter of 2025,… [Read More]

3 days ago